← Back to Patent Explorer
US4966769A Expired / Lapsed US ⏱️ 0.0 years remaining

Method for delivering dosage form for diltiazem

Assignee: Alza Corp
•
Filing: 1989-05-11
•
Granted: 1990-10-30
•
Expires: 2009-05-11
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A device is disclosed for delivering diltiazem at a controlled and substantially zero order rate over a prolonged period of time.

Inventors

  • 👤 George V. Guittard
  • 👤 Patrick S. L. Wong
  • 👤 Felix Theeuwes
  • 👤 Richard Cortese

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-02 20:36
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0002; A61K9/0004; A61K31/00; A61K31/33; A61K31/395; A61K31/55

Claims Analysis

Total Claims: 7
Claim 1
Independent Claim 225 words
A method for delivering diltiazem to a recipient in need thereof, which method comprises: (a) admitting orally into the recipient a device comprising: (1) a wall surrounding and forming a compartment, which compartment comprises: (A) a diltiazem composition comprising from 70 wt % to 96 wt % of a member selected from the group consisting of diltiazem and its pharmaceutically acceptable salts, from 0.5 wt % to 15 wt % of polyacrylic acid comprising a 2,500,000 to 4,000,000 molecular weight, from 0.5 wt % to 20 wt % of a poly(ethylene oxide) comprising a 4,000,000 to 5,500,000 molecular weight, and from 0.5 wt % to 20 wt % of a poly(vinyl pyrrolidone) comprising a 35,000 to 40,000 molecular weight; (B) a push composition comprising from 70 wt % to 95 wt % of poly(ethylene oxide) comprising a 6,200,000 to 7,500,000 molecular weight, from 1 wt % to 20 wt % of an osmagent, and from 1 wt % to 15 wt % of a hydroxypropylmethylcellulose comprising a 9,000 to 16,000 molecular weight; (2) at least one passageway in the wall; and, (b) delivering diltiazem by the device imbibing fluid through the wall into the compartment to cause the diltiazem composition to form a dispensable composition and to cause the push composition to push the diltiazem composition through the passageway for delivering diltiazem to the recipient.
Claim 2
Independent Claim 225 words
A method for delivering diltiazem to a recipient in need thereof, which method comprises: (a) admitting orally into the recipient a device comprising: (1) a wall surrounding and forming a compartment, which compartment comprises: (A) a diltiazem composition comprising from 70 wt % to 96 wt % of a member selected from the group consisting of diltiazem and its pharmaceutically acceptable salts, from 0.5 wt % to 15 wt % of polyacrylic acid comprising a 2,500,000 to 4,000,000 molecular weight, from 0.5 wt % to 20 wt % of a poly(ethylene oxide) comprising a 4,000,000 to 5,500,000 molecular weight, and from 0.5 wt % to 20 wt % of a poly(vinyl pyrrolidone) comprising a 35,000 to 40,000 molecular weight; (B) a push composition comprising from 70 wt % to 95 wt % of poly(ethylene oxide) comprising a 6,200,000 to 7,500,000 molecular weight, from 1 wt % to 20 wt % of an osmagent, and from 1 wt % to 15 wt % of a hydroxypropylmethylcellulose comprising a 9,000 to 16,000 molecular weight; (2) at least one passageway in the wall; and, (b) delivering diltiazem by the device imbibing fluid through the wall into the compartment to cause the diltiazem composition to form a dispensable composition and to cause the push composition to push the diltiazem composition through the passageway for delivering diltiazem to the recipient.
Claim 3
Independent Claim 183 words
A method for delivering diltiazem to a recipient in need thereof, which method comprises: (a) admitting orally into the recipient a dosage form comprising: (1) a wall comprising at least in part a composition, which composition comprises a member selected from the group consisting of a cellulose ester, cellulose ether, cellulose ester-ether, cellulose acylate, cellulose diacylate, cellulose acetate, cellulose diacetate and cellulose triacetate, which wall surrounds; (2) a compartment; (3) an osmotic core in the compartment, which core comprises from 30 mg to 500 mg of a member selected from the group consisting of diltiazem and its pharmaceutically acceptable salts, wherein the salt is a member selected from the group consisting of hydrochloride, hydrobromide, sulfate, phosphate, lactate, citrate, tartrate, malate, maleate, fumarate, ascorbate, gluconate, aspartatate, and salicylate; (4) means in the wall for delivering diltiazem from the dosage form, said means comprising a leached passageway formed in the wall when the dosage form is in the recipient, and, (b) delivering from the osmotic core from 30 mg up to 500 mg of diltiazem through the leached passageway to the recipient over 24 hours.
Claim 4
Independent Claim 183 words
A method for delivering diltiazem to a recipient in need thereof, which method comprises: (a) admitting orally into the recipient a dosage form comprising: (1) a wall comprising at least in part a composition, which composition comprises a member selected from the group consisting of a cellulose ester, cellulose ether, cellulose ester-ether, cellulose acylate, cellulose diacylate, cellulose acetate, cellulose diacetate and cellulose triacetate, which wall surrounds; (2) a compartment; (3) an osmotic core in the compartment, which core comprises from 30 mg to 500 mg of a member selected from the group consisting of diltiazem and its pharmaceutically acceptable salts, wherein the salt is a member selected from the group consisting of hydrochloride, hydrobromide, sulfate, phosphate, lactate, citrate, tartrate, malate, maleate, fumarate, ascorbate, gluconate, aspartatate, and salicylate; (4) means in the wall for delivering diltiazem from the dosage form, said means comprising a leached passageway formed in the wall when the dosage form is in the recipient, and, (b) delivering from the osmotic core from 30 mg up to 500 mg of diltiazem through the leached passageway to the recipient over 24 hours.
Claim 5
Dependent Claim 29 words
The method for delivering diltiazem to the recipient in need thereof according to claim 1, wherein the leached passageway is replaced by an erodible diltiazem release rate controlling pore.
Claim 6
Dependent Claim 25 words
The method for delivering diltiazem to the recipient in need thereof according to claim 1, wherein the leached passageway is replaced by a drilled passageway.
Claim 7
Dependent Claim 32 words
The method for delivering diltiazem to the recipient in need thereof according to claim 1, wherein the recipient comprises a gastrointestinal fluid and the diltiazem exhibits solubility in gastric and intestinal fluid.

References Cited (Backward Citations)

US3845770A Cited
US3916899A Cited
US4088864A Cited
US4063064A Cited
US4111202A Cited
US4160452A Cited
US4200098A Cited
US4285987A Cited
US4235236A Cited
US4783337A Cited
US4684524A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1993-10-29 1994-04-30 1994-10-30 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1997-10-29 1998-04-30 1998-10-30 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2001-10-29 2002-04-30 2002-10-30 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag